Promise of new Alzheimer's drug is dashed after lack of evidence

BMJ. 2016 Nov 24:355:i6362. doi: 10.1136/bmj.i6362.
No abstract available

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Aged
  • Alzheimer Disease / drug therapy*
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • Drug Approval*
  • Humans
  • Treatment Failure

Substances

  • Antibodies, Monoclonal, Humanized
  • solanezumab